A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer

PURPOSE: Cabozantinib is a multi-kinase inhibitor that targets MET, AXL, and VEGFR2, and may synergize with EGFR inhibition in NSCLC. Cabozantinib was assessed alone or in combination with erlotinib in patients with progressive NSCLC and EGFR mutations who had previously received erlotinib. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Wakelee, Heather A., Gettinger, Scott, Engelman, Jeffrey, Jänne, Pasi A., West, Howard, Subramaniam, Deepa S., Leach, Joseph, Wax, Michael, Yaron, Yifah, Miles, Dale R., Lara, Primo N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5403837/
https://www.ncbi.nlm.nih.gov/pubmed/28352985
http://dx.doi.org/10.1007/s00280-017-3283-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5403837/
https://www.ncbi.nlm.nih.gov/pubmed/28352985
http://dx.doi.org/10.1007/s00280-017-3283-z

Ejemplares similares